S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:INVA

Innoviva (INVA) Stock Forecast, Price & News

$12.90
-0.03 (-0.23%)
(As of 09/22/2023 ET)
Compare
Today's Range
$12.87
$13.17
50-Day Range
$12.43
$13.89
52-Week Range
$10.64
$13.90
Volume
570,028 shs
Average Volume
650,559 shs
Market Capitalization
$839.79 million
P/E Ratio
5.71
Dividend Yield
N/A
Price Target
$15.17

Innoviva MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
17.6% Upside
$15.17 Price Target
Short Interest
Bearish
13.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
1.02mentions of Innoviva in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

807th out of 962 stocks

Pharmaceutical Preparations Industry

383rd out of 454 stocks


INVA stock logo

About Innoviva (NASDAQ:INVA) Stock

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

INVA Price History

INVA Stock News Headlines

Are "The Magnificent Seven" the Next Sears?
The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.
Innoviva (NASDAQ: INVA)
Are "The Magnificent Seven" the Next Sears?
The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.
Innoviva's Reward Isn't Worth The Risk
Innoviva Announces Retirement of Board Chairman
Is Innoviva (INVA) Stock Undervalued Right Now?
Still Avoiding Innoviva
See More Headlines
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Company Calendar

Last Earnings
8/02/2023
Today
9/24/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CUSIP
88338T10
Employees
101
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$15.17
High Stock Price Forecast
$22.50
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+17.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$213.92 million
Pretax Margin
92.51%

Debt

Sales & Book Value

Annual Sales
$331.34 million
Cash Flow
$2.32 per share
Book Value
$8.11 per share

Miscellaneous

Free Float
64,187,000
Market Cap
$839.79 million
Optionable
Optionable
Beta
0.53

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Pavel Raifeld C.F.A. (Age 39)
    Chief Exec. Officer
    Comp: $754.67k
  • Ms. Marianne Zhen CPA (Age 54)
    Chief Accounting Officer & Sec.
    Comp: $530.21k
  • Mr. Stephen Basso M.B.A.
    Chief Financial Officer













INVA Stock - Frequently Asked Questions

Should I buy or sell Innoviva stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings
or view top-rated stocks.

What is Innoviva's stock price forecast for 2023?

3 brokerages have issued twelve-month target prices for Innoviva's shares. Their INVA share price forecasts range from $10.00 to $22.50. On average, they anticipate the company's share price to reach $15.17 in the next year. This suggests a possible upside of 17.6% from the stock's current price.
View analysts price targets for INVA
or view top-rated stocks among Wall Street analysts.

How have INVA shares performed in 2023?

Innoviva's stock was trading at $13.25 on January 1st, 2023. Since then, INVA shares have decreased by 2.6% and is now trading at $12.90.
View the best growth stocks for 2023 here
.

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our INVA earnings forecast
.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) posted its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported $0.08 EPS for the quarter. The biotechnology company had revenue of $80.99 million for the quarter. Innoviva had a net margin of 80.35% and a trailing twelve-month return on equity of 19.28%.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a variety of institutional and retail investors. Top institutional investors include Shaolin Capital Management LLC (0.00%), Dimensional Fund Advisors LP (5.99%), Renaissance Technologies LLC (5.52%), State Street Corp (3.66%), Geode Capital Management LLC (1.81%) and Pacer Advisors Inc. (1.35%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline.
View institutional ownership trends
.

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $12.90.

How much money does Innoviva make?

Innoviva (NASDAQ:INVA) has a market capitalization of $839.79 million and generates $331.34 million in revenue each year. The biotechnology company earns $213.92 million in net income (profit) each year or $2.26 on an earnings per share basis.

How many employees does Innoviva have?

The company employs 101 workers across the globe.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690.

This page (NASDAQ:INVA) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -